PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
738.04%
R&D change of 738.04% while AXSM maintains spending. Bruce Berkowitz would investigate effectiveness.
40.95%
G&A change of 40.95% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
178.81%
Operating expenses change of 178.81% while AXSM maintains costs. Bruce Berkowitz would investigate control.
178.81%
Total costs change of 178.81% while AXSM maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
D&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
-184.06%
EBITDA decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-178.81%
Operating income decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.77%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-184.01%
Pre-tax income decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Net income decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-184.12%
EPS decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
-184.12%
Diluted EPS decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.